Cintia Piccina Sells 6,713 Shares of Autolus Therapeutics (NASDAQ:AUTL) Stock

by · The Markets Daily

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) insider Cintia Piccina sold 6,713 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $2.34, for a total transaction of $15,708.42. Following the sale, the insider owned 13,287 shares of the company’s stock, valued at approximately $31,091.58. This represents a 33.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Autolus Therapeutics Stock Up 2.2%

Autolus Therapeutics stock traded up $0.05 during trading hours on Thursday, hitting $2.29. The company had a trading volume of 1,772,956 shares, compared to its average volume of 1,811,079. The firm has a market capitalization of $609.51 million, a P/E ratio of -2.16 and a beta of 2.10. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.89 and a quick ratio of 4.40. The firm’s fifty day moving average is $1.86 and its 200-day moving average is $1.66. Autolus Therapeutics PLC Sponsored ADR has a fifty-two week low of $1.17 and a fifty-two week high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The company had revenue of $45.69 million during the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AUTL shares. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

View Our Latest Report on Autolus Therapeutics

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marex Group plc bought a new stake in Autolus Therapeutics during the second quarter worth approximately $28,000. Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $28,000. GAMMA Investing LLC lifted its stake in shares of Autolus Therapeutics by 115.6% in the second quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after buying an additional 8,309 shares during the last quarter. SmartHarvest Portfolios LLC acquired a new stake in shares of Autolus Therapeutics in the fourth quarter worth $43,000. Finally, Waverly Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 1st quarter worth $37,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Recommended Stories